C. Rauch

462 total citations
32 papers, 355 citations indexed

About

C. Rauch is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, C. Rauch has authored 32 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 17 papers in Genetics and 16 papers in Pathology and Forensic Medicine. Recurrent topics in C. Rauch's work include Chronic Lymphocytic Leukemia Research (15 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Lymphoma Diagnosis and Treatment (13 papers). C. Rauch is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Lymphoma Diagnosis and Treatment (13 papers). C. Rauch collaborates with scholars based in Germany, Italy and France. C. Rauch's co-authors include Rieke Alten, M. Chartier, H. Nüßlein, Manuela Le Bars, Mauro Galeazzi, Coralie Poncet, Hanns‐Martin Lorenz, Xavier Mariette, Michael T. Nurmohamed and W. Bensen and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

C. Rauch

28 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Rauch Germany	11	259	81	81	79	76	32	355
L.G. Schipper Netherlands	6	315 1.2×	75 0.9×	16 0.2×	67 0.8×	120 1.6×	13	364
Elaine Yu United States	8	223 0.9×	53 0.7×	20 0.2×	34 0.4×	76 1.0×	15	329
J. Wendler Germany	8	201 0.8×	25 0.3×	26 0.3×	53 0.7×	91 1.2×	26	318
Kirsten Karberg Germany	9	349 1.3×	17 0.2×	43 0.5×	30 0.4×	91 1.2×	40	428
Е. П. Иливанова Russia	6	356 1.4×	79 1.0×	56 0.7×	51 0.6×	167 2.2×	21	448
Emina Omerovic Denmark	8	191 0.7×	41 0.5×	8 0.1×	43 0.5×	56 0.7×	11	324
V. Martínez Taboada Spain	7	138 0.5×	28 0.3×	38 0.5×	19 0.2×	54 0.7×	15	198
Ana M. Suelves United States	10	92 0.4×	21 0.3×	79 1.0×	43 0.5×	15 0.2×	21	400
Hedley Griffiths Australia	12	249 1.0×	77 1.0×	8 0.1×	47 0.6×	127 1.7×	31	304
Mieke F. Pouw Netherlands	4	125 0.5×	36 0.4×	65 0.8×	13 0.2×	49 0.6×	6	285

Countries citing papers authored by C. Rauch

Since Specialization

Citations

This map shows the geographic impact of C. Rauch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Rauch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Rauch more than expected).

Fields of papers citing papers by C. Rauch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Rauch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Rauch. The network helps show where C. Rauch may publish in the future.

Co-authorship network of co-authors of C. Rauch

This figure shows the co-authorship network connecting the top 25 collaborators of C. Rauch. A scholar is included among the top collaborators of C. Rauch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Rauch. C. Rauch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alten, Rieke, Hans‐Peter Tony, Bettina Bannert, et al.. (2023). Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus. Clinical Rheumatology. 42(9). 2321–2334. 1 indexed citations

Alten, Rieke, Xavier Mariette, René‐Marc Flipo, et al.. (2022). Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clinical Rheumatology. 41(8). 2361–2373. 14 indexed citations

Alten, Rieke, Xavier Mariette, René‐Marc Flipo, et al.. (2021). OP0180 IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA. Annals of the Rheumatic Diseases. 80. 108–108.

Alten, Rieke, Eugen Feist, Hanns‐Martin Lorenz, et al.. (2019). Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. Clinical Rheumatology. 38(11). 3049–3059. 5 indexed citations

Peichl, P., Rieke Alten, Mauro Galeazzi, et al.. (2019). Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. Wiener Medizinische Wochenschrift. 170(5-6). 132–140. 6 indexed citations

Alten, Rieke, Xavier Mariette, Hanns‐Martin Lorenz, et al.. (2019). Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clinical Rheumatology. 38(5). 1413–1424. 27 indexed citations

Alten, Rieke, Harald Burkhardt, Eugen Feist, et al.. (2018). Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Arthritis Research & Therapy. 20(1). 1–1. 21 indexed citations

Alten, Rieke, H. Nüßlein, Xavier Mariette, et al.. (2017). Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD Open. 3(1). e000345–e000345. 35 indexed citations

Alten, Rieke, H.-M. Lorenz, Xavier Mariette, et al.. (2017). FRI0245 Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world action study. Annals of the Rheumatic Diseases. 76. 577–578. 2 indexed citations

10.

Mariette, Xavier, Rieke Alten, H. Nüßlein, et al.. (2016). The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine. 84(5). 571–576. 16 indexed citations

11.

Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2016). Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.. PubMed. 34(3). 489–99. 29 indexed citations

12.

Alten, Rieke, H. Nüßlein, M. Galeazzi, et al.. (2016). THU0066 Do Predictors of IV Abatacept Retention Depend on The Line of Rheumatoid Arthritis Treatment: 12-Month Interim Analysis of The Observational, Prospective Action Study. Annals of the Rheumatic Diseases. 75. 202–202. 1 indexed citations

13.

Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2015). Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders. 16(1). 176–176. 34 indexed citations

14.

Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2014). Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskeletal Disorders. 15(1). 14–14. 41 indexed citations

15.

Alten, Rieke, M. Galeazzi, Hanns‐Martin Lorenz, et al.. (2014). SAT0245 Decreased Use of Glucocorticoids in PTS with RA Who Initiated IV Abatacept and Previously Failed at Least One Biologic Agent: Results from the 2-Year Action Study. Annals of the Rheumatic Diseases. 73. 681–681. 1 indexed citations

16.

Alten, Rieke, M. Galeazzi, H.-M. Lorenz, et al.. (2014). FRI0318 Two-Year Retention and Effectiveness of IV Abatacept in Real-Life Setting: Results from the Action Study. Annals of the Rheumatic Diseases. 73. 500–501. 3 indexed citations

17.

Weih, Markus, Dixie Harms, C. Rauch, et al.. (2008). Qualitätsverbesserung von Multiple-Choice-Prüfungen. Der Nervenarzt. 80(3). 324–328. 4 indexed citations

18.

Heckmann, Josef G., C. Rauch, Matthias Dütsch, et al.. (2008). ERlanger Neurologisches Examen – STrukturiert (ERNEST). Der Nervenarzt. 79(6). 676–683. 2 indexed citations

19.

Heckmann, Josef G., Matthias Dütsch, C. Rauch, et al.. (2008). Effects of peer‐assisted training during the neurology clerkship: a randomized controlled study. European Journal of Neurology. 15(12). 1365–1370. 50 indexed citations

20.

Stemper, Brigitte, et al.. (2003). Thrombolyse-Therapie beim akuten Schlaganfall. Nervenheilkunde. 22(10). 488–493. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact